Table 1.
This study included 706 patients who received BT in our hospital from July 2004 to January 2014. Of 706 patients, 265 (38%) were treated with combined BT and external beam radiation therapy (EBRT). Half of the patients were classified as clinical T1c, and 340 patients (48%) had an intermediate risk based on the D’Amico risk classification.
| BT as monotherapy | 441 (62%) |
| BT + EBRT | 265 (38%) |
| None | 390 (55%) |
| Neoadjuvant ADT | 243 (35%) |
| Adjuvant ADT | 10 (1%) |
| Neo ADT/ adjuvant ADT | 63 (9%) |
| Clinical stage | |
| T1c | 351 (50%) |
| T2a | 239 (34%) |
| T2b | 58 (8%) |
| T2c | 30 (4%) |
| T3a | 28 (4%) |
| D‘Amico risk classification | |
| Low risk | 248 (35%) |
| Intermediate risk | 340 (48%) |
| High risk (including cT3a) | 118 (17%) |
| Gleason Score | |
| −6 | 322 (45%) |
| 7 | 323 (46%) |
| 8- | 61 (9%) |
| Median age (years) | 70 (range 48–84) |
| Median PSA (ng/mL) | 7.16 (range 1.17–113) |
| Median PV (mL) | 24.6 (range 7.7–61.9) |
| Mean total IPSS | 7.99 (range 0–33) |
| Mean IPSS-QOL score | 3.9 (range 0–6) |
| Mean total OABSS | 3.45 (range 0–14) |
BT = brachytherapy, EBRT = external beam radiation therapy, ADT = androgen deprivation therapy, PSA = prostate-specific antigen, PV = prostate volume, IPSS = International Prostate Symptom Score, OABSS = Overactive Bladder Symptom Score.